-
Cowen & Co. Reiterates Outperform Rating On King Pharmaceuticals (KG)
Monday, April 5, 2010 - 10:59am | 134Read More...According to analysts at Cowen & Co., Embeda NRx trends are improving in Q1 2010 at King Pharmaceuticals (NYSE: KG). The report estimates that Embeda had sales of $90 million in 2010, $175 million in 2011, $240 million in 2012, $290 million in 2013, and $375 million in 2015. The analysts wrote...
-
Cowen & Co. Sees Opportunity In DreamWorks (DWA)
Monday, March 29, 2010 - 12:25pm | 180Read More...In a research note released today, analysts from Cowen & Co. wrote that the soft opening of "How to Train Your Dragon," may present an opportunity for investors to buy DreamWorks (NYSE: DWA) shares at a discount. The analysts wrote, "Our concerns about soft pre-release audience interest proved...
-
Flurry Of Upcoming Events Could Trigger Santarus Shares Over Next 2-3 Months
Tuesday, November 24, 2009 - 9:34am | 135Read More...This Morning Cowen & Co. reiterated their “Neutral” rating for Santarus, Inc. (NASDAQ: SNTS), while raising their estimates for the company. The Firm said Santarus faces three key events over the next 2-3 months, at least two of which could significantly move the shares. The most important...
